GLENMARK PHARMACEUTICALS
Back to Balance Sheet
|
GLENMARK PHARMACEUTICALS Last 5 Year Contingent Liabilities History
[Consolidated]
| Mar2026 | Mar2025 | Mar2024 | Mar2023 | Mar2022 | |
|---|---|---|---|---|---|
| Contingent Liabilities | ₹788 Cr | ₹800 Cr | ₹1,063 Cr | ₹337 Cr | ₹361 Cr |
What is the latest Contingent Liabilities ratio of GLENMARK PHARMACEUTICALS ?
| Year | Contingent Liabilities |
|---|---|
| Mar2026 | ₹788 Cr |
| Mar2025 | ₹800 Cr |
| Mar2024 | ₹1,063 Cr |
| Mar2023 | ₹337 Cr |
| Mar2022 | ₹361 Cr |
How is Contingent Liabilities of GLENMARK PHARMACEUTICALS Trending?
| Years | Contingent Liabilities | % Change | |
|---|---|---|---|
| Mar2026 | ₹788 Cr | -1.56 | |
| Mar2025 | ₹800 Cr | -24.74 | |
| Mar2024 | ₹1,063 Cr | 215.81 | |
| Mar2023 | ₹337 Cr | -6.81 | |
| Mar2022 | ₹361 Cr | - | |
Compare Contingent Liabilities of peers of GLENMARK PHARMACEUTICALS
| Peers & Returns | Market Capitalization | 1 Week | 1 Month | 1 Year | ||
| GLENMARK PHARMACEUTICALS | ₹69,539.7 Cr | 1% | 13.1% | 27.5% | Stock Analytics | |
| SUN PHARMACEUTICAL INDUSTRIES | ₹463,180.0 Cr | 1.6% | -1% | 22.2% | Stock Analytics | |
| DIVIS LABORATORIES | ₹243,302.0 Cr | 1.7% | 10.1% | 49.4% | Stock Analytics | |
| TORRENT PHARMACEUTICALS | ₹188,623.0 Cr | 1.5% | -1.2% | 38.2% | Stock Analytics | |
| CIPLA | ₹114,554.0 Cr | 0.7% | -3.5% | -10.4% | Stock Analytics | |
| DR REDDYS LABORATORIES | ₹97,741.0 Cr | -1.3% | 0.1% | -7.8% | Stock Analytics | |
GLENMARK PHARMACEUTICALS Share Price vs Sensex
| Share Price Returns(%) | 1 Week | 1 Month | 1 Year |
| GLENMARK PHARMACEUTICALS | 1% |
13.1% |
27.5% |
| SENSEX | -0.9% |
-1.5% |
-5.8% |
You may also like the below Video Courses